+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Obsessive Compulsive Disorder Treatment Market Report and Forecast 2023-2031

  • PDF Icon


  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797885
The global obsessive-compulsive disorders treatment market size attained a value of USD 466.2 million in 2022. The market is anticipated to grow at a CAGR of 9.1% during the forecast period of 2023-2031 to attain a value of USD 1,022.7 million by 2031.

Global Obsessive Compulsive Disorder Treatment Market: Introduction

Obsessive-Compulsive Disorder (OCD) is a common, chronic, and long-lasting mental health disorder in which a person has uncontrollable, recurring thoughts (obsessions) and/or behaviours (compulsions) that they feel the urge to repeat over and over.

Obsessions are repeated thoughts, urges, or mental images that cause anxiety. Examples include fear of germs or contamination, unwanted forbidden or taboo thoughts involving sex, religion, and harm, or having things symmetrical or in a perfect order.

Compulsions are repetitive behaviours that a person with OCD feels the urge to do in response to an obsessive thought. Common compulsions include excessive cleaning and/or handwashing, arranging things in a, precise way, repeatedly checking on things, such as repeatedly checking to see if the door is locked or that the oven is off, or compulsive counting.

OCD is typically treated with medication, psychotherapy, or a combination of the two.
  • Medication: Certain psychiatric medications can help control the obsessions and compulsions of OCD. Most commonly, selective serotonin reuptake inhibitors (SSRIs), and fluoxetine (Prozac), fluvoxamine, and sertraline (Zoloft) are prescribed
  • Psychotherapy: Cognitive-behavioural therapy (CBT) is effective for many people with OCD. CBT involves retraining your thought patterns and routines so that compulsive behaviours are no longer necessary. One type of CBT, known as Exposure and Response Prevention (ERP), is particularly useful
  • Neuromodulation: In severe cases of OCD that do not respond to the usual treatments, neuromodulation techniques such as deep brain stimulation (DBS) or transcranial magnetic stimulation (TMS) may be considered
While OCD is a chronic condition, with proper treatment, most people with OCD can achieve substantial relief from their symptoms and improve their quality of life.

Global Obsessive Compulsive Disorder Epidemiology
Obsessive-Compulsive Disorder (OCD) is a widespread mental health condition affecting people globally, with significant variations in prevalence, age of onset, gender predisposition, and lifestyle influences.
  • Prevalence: OCD is a common disorder that affects about 1-2% of the population. It is present worldwide, in both developed and developing countries, indicating a global need for effective treatments and interventions
  • Age: OCD can start at any age from preschool to adulthood, but it typically begins in adolescence or early adulthood. The onset of OCD is typically earlier in males than in females
  • Gender: Men and women are equally likely to develop OCD. However, as mentioned above, the age of onset is often earlier in males. The themes of obsessions or compulsions may differ by gender
  • Lifestyle Habits: While the exact cause of OCD is not known, a combination of genetic, neurobiological, behavioral, cognitive, and environmental factors may contribute to the development of the disorder. Stressful life events, both acute and chronic, may precipitate the onset of OCD, but they are not thought to be a primary cause of the disorder
The OCD treatment market is divided based on these epidemiological factors. The market for pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs), forms a significant part of the OCD market, given that these are often the first line of treatment. Cognitive-behavioral therapy (CBT), specifically exposure and response prevention (ERP), is another crucial segment of the market.

Geographically, regions with higher populations and better access to mental health services account for a larger share of the market. The highest per capita rates of OCD are reported in the United States and Europe, but emerging economies such as India and China also represent significant markets due to their large population base.

Overall, the market for OCD treatments is robust and diverse, reflecting the global prevalence of the disorder and the variety of treatment approaches available. As our understanding of OCD continues to evolve, it is likely that new therapeutic targets and treatment methods will emerge, further expanding the market.

Global Obsessive Compulsive Disorder Treatment Market Segmentations

The market can be categorised into age group, therapy type, severity, treatment channel, and region.

Global Obsessive Compulsive Disorder Treatment Market Breakup by Age group

  • Adults
  • Paediatrics
  • Other

Global Obsessive Compulsive Disorder Treatment Market Breakup by Therapy type

  • Cognitive Behavioural Therapy
  • Augmentation Therapy
  • Aversion Therapy
  • Systematic Desensitization
  • Others

Global Obsessive Compulsive Disorder Treatment Market Breakup by Severity

  • Mild
  • Moderate
  • Severe
  • Other

Global Obsessive Compulsive Disorder Treatment Market Breakup by Treatment Channel

  • Public
  • Private

GlobalGlobal Obsessive Compulsive Disorder Treatment Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Global Obsessive Compulsive Disorder Treatment Market Scenario

  • The global obsessive-compulsive disorder (OCD) treatment market is on a path of steady growth, driven by a multitude of factors such as increasing prevalence of the disorder, growing awareness about mental health issues, and advancements in therapeutic options
  • As of now, the market is primarily divided into two main segments: pharmaceutical treatments and psychotherapy. The pharmaceutical sector holds a substantial portion of the market share, with drugs such as selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) being the most prescribed medications for managing OCD symptoms. These medications have proven efficacy and are usually the first line of treatment
  • Psychotherapy, particularly cognitive-behavioural therapy (CBT), is another significant segment of the OCD treatment market. Exposure and Response Prevention (ERP), a type of CBT, has been shown to be highly effective in treating OCD and is becoming increasingly accessible to patients, both in-person and through digital platforms
  • The growing prevalence of digital and online mental health services is another important trend in the OCD treatment market. As technology continues to advance, teletherapy and online CBT programs are becoming more widespread, making therapy more accessible to a broader range of patients. This is particularly relevant in the context of the COVID-19 pandemic, which has accelerated the adoption of telehealth services
  • Geographically, North America holds a substantial share of the OCD treatment market, primarily due to higher awareness about mental health, advanced healthcare infrastructure, and higher healthcare spending. However, the market in Asia-Pacific is expected to grow at a rapid pace due to increasing mental health awareness and improving healthcare infrastructure
  • The OCD treatment market also faces challenges. Despite the availability of effective treatments, a significant proportion of individuals with OCD do not receive the help they need. This treatment gap is due to factors such as stigma associated with mental health disorders, lack of access to mental health services, and misdiagnosis or delayed diagnosis of OCD
In conclusion, the global OCD treatment market is poised for considerable growth in the coming years. The increasing prevalence of the disorder, coupled with growing awareness and advancements in treatment options, are the main drivers of this market growth. However, challenges such as reducing the treatment gap and improving access to mental health services need to be addressed to optimize the market's potential.

Key Players in the Global Obsessive Compulsive Disorder Treatment Market

The report gives an in-depth analysis of the key players involved in the global obsessive compulsive disorder treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

Sun Pharmaceutical Industries Ltd.

H. Lundbeck A/S
Teva Pharmaceuticals USA, Inc.

Elli Lilly & Company
Apotex Inc
Viatris Inc
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
Pfizer Inc.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology3 Executive Summary
4 Obsessive-Compulsive Disorder Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview Patent Status and Expiry Timelines from Drug Development to Commercial Launch New Drug Application Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview US FDA EU EMA INDIA CDSCO JAPAN PMDA Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-out Analysis
7.3 Awareness and Prevention Gaps
8 Global Obsessive-Compulsive Disorder Treatment Market
8.1 Global Obsessive-Compulsive Disorder Treatment Market Overview
8.2 Global Obsessive-Compulsive Disorder Treatment Market Analysis
8.2.1 Market Overview Global Historical Obsessive-Compulsive Disorder Treatment Market Value (2016-2022) Global Forecast Obsessive-Compulsive Disorder Treatment Market Value (2023-2031)
8.3 Global Obsessive-Compulsive Disorder Treatment Market by Age Group
8.3.1 Market Overview Adults Paediatrics Others
8.4 Global Obsessive-Compulsive Disorder Treatment Market by Therapy Type
8.4.1 Market Overview Cognitive Behavioural Therapy Augmentation Therapy Aversion Therapy Systematic Desensitization Others
8.5 Global Obsessive-Compulsive Disorder Treatment Market by Severity
8.5.1 Market Overview Mild Moderate Severe Others
8.6 Global Obsessive-Compulsive Disorder Treatment Market by Treatment Channel
8.6.1 Market Overview Public Private
8.7 Global Obsessive-Compulsive Disorder Treatment Market by Region
8.7.1 Market Overview North America Europe Asia Pacific Middle East and Africa Latin America
9 North America Obsessive-Compulsive Disorder Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Obsessive-Compulsive Disorder Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Obsessive-Compulsive Disorder Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Obsessive-Compulsive Disorder Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Obsessive-Compulsive Disorder Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Obsessive-Compulsive Disorder Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Sun Pharmaceutical Industries Ltd.
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 H. Lundbeck A/S
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Teva Pharmaceuticals USA, Inc.
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Elli Lilly & Company
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Apotex Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Viatris Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Lannett
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 GlaxoSmithKline Plc
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 F. Hoffmann-La Roche Ltd
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Pfizer Inc.
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
16 Global Obsessive-Compulsive Disorder Treatment Market Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket

Companies Mentioned

  • Sun Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
  • Teva Pharmaceuticals Usa, Inc.
  • Elli Lilly & Company
  • Apotex Inc.
  • Viatris Inc.
  • Lannett
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.



Table Information